Obinutuzumab for the treatment of lupus kidney disease with membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of lupus (SLE) and a kidney biopsy within the last 12 months showing only class 5 lupus nephritis.
- You must be between 18 and 75 years old.
- You must have significant protein in your urine (either more than 3 grams per day, or more than 1 gram per day despite standard blood pressure and kidney-protecting medications).
- You must have a positive antinuclear antibody (ANA) blood test.
- In the last 2 months, you must not have taken certain immunosuppressants like cyclophosphamide, tacrolimus, ciclosporin, mycophenolate mofetil, or pulse steroids.
- If you are of childbearing age, you must agree to use effective contraception during the trial and for 18 months after the last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests a new medicine called O-triple for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if it can control the disease and help protect kidney function.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.